Status:
COMPLETED
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children
Lead Sponsor:
Novartis Vaccines
Conditions:
Prevention of Meningococcal Infection
Eligibility:
All Genders
7-16 years
Phase:
PHASE3
Brief Summary
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in healthy children
Detailed Description
The aim of this study is to investigate the immunogenicity offered by MenCC vaccine when administered in different schedules at different years of life: 2 doses in the first year of life given 2 month...
Eligibility Criteria
Inclusion
- healthy infants
Exclusion
- known hypersensitivity to any vaccine component
- significant acute or chronic infections
- previously ascertained or suspected disease caused by N. meningitidis
- previous household contact with an individual with a positive culture of N. meningitidis serogroup C
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
257 Patients enrolled
Trial Details
Trial ID
NCT00311415
Start Date
October 1 2005
End Date
April 1 2008
Last Update
February 8 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mainz, Kehl, Neumünster, Ettenheim, Germany
2
Kraków, Lubartów, Lublin, Bydgosczcz, Poland